Amount Raised
$75 Million
Round Type
Series D
PhiladelphiaBiotechnologyHealth CareTherapeuticsInvestors
Description
FORE Biotherapeutics today announced the closing of its $75 million Series D financing, led by the SR One and co-led by Medicxi and joined by existing investors. FORE Biotherapeutics’ syndicate now includes new investor Medicxi, as well as existing investors OrbiMed, HBM Healthcare Investments, Novartis Venture Fund, 3B Future Health Fund, Cormorant Asset Management, Wellington Management and Samsung Securities. In connection with the financing, Giovanni Mariggi, Partner at Medicxi, was appointed to FORE Biotherapeutics’ Board of Directors.
Quick answer
Fore Biotherapeutics raised $75 Million in a Series D round, dated August 24, 2023. Investors: Wellington Management, Cormorant Asset Management, 3 B Future Health Fund, Novartis Venture Fund, HBM Healthcare Investments, Orbi Med, Medicxi and SR One. Fore Biotherapeutics is based in Philadelphia, Pennsylvania, United States.
- How much did Fore Biotherapeutics raise?
- Fore Biotherapeutics raised $75 Million in a Series D round on August 24, 2023.
- Who invested in Fore Biotherapeutics?
- Wellington Management, Cormorant Asset Management, 3 B Future Health Fund, Novartis Venture Fund, HBM Healthcare Investments, Orbi Med, Medicxi and SR One are named as investors in this round.
- What does Fore Biotherapeutics do?
- Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers.
- Where is Fore Biotherapeutics based and how big is it?
- Fore Biotherapeutics is based in Philadelphia, Pennsylvania, United States. Fundz records about 56 employees.
- Who are the decision-makers at Fore Biotherapeutics?
- Fundz holds 5 contacts at Fore Biotherapeutics, including the Founder & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Fore Biotherapeutics that raised within 45 days of this round, from Fundz verified event records.
- Amicus Therapeutics raised an undisclosed amount (Funding Round) on October 2, 2023.
- Acasti raised $7.5M (Post-IPO Equity) on September 26, 2023.
- Acasti raised $7.5M on September 25, 2023.
- Qihan Biotech raised an undisclosed amount (Series B) on September 23, 2023.
- DalCor Pharmaceuticals raised $80M (Series D) on September 13, 2023.
- Renibus Therapeutics raised an undisclosed amount (Series B) on September 12, 2023.
Who to call at Fore Biotherapeutics, and when
A new round usually means Fore Biotherapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Fore Biotherapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Fore Biotherapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Fore Biotherapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Fore Biotherapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Fore Biotherapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.